Polypharmacy in a case of refractory major depression: Part II: Implications for clinical management

Journal of Psychiatric Practice

Volumn 9, Issue 1, 2003, Pages 71-78

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DIAZEPAM; FLURAZEPAM; FUROSEMIDE; PROPRANOLOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANXIETY; AUTOPSY; CASE REPORT; CAUSE OF DEATH; COMORBIDITY; DRUG BLOOD LEVEL; EDEMA; HUMAN; MAJOR DEPRESSION; MALE; POLYPHARMACY; REVIEW;

EID: 0038614936     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200301000-00007     Document Type: Review

References (32)

1. Preskorn SH. Polypharmacy in a patient with refractory major depression: Part I. The case. Journal of Psychiatric Practice 2002;8:370-6.
2. Preskorn SH. Marooned: Only one choice. J Pract Psychiatry Behav Health 1998;4:110-4.
3. Charney DS, Mihic SJ, Harris RA. Hypnotics and sedatives. In: Hardman JG, Limbird LE. Goodman & Gilman's the pharmacological basis of therapeutics, 10th edition. New York: McGraw-Hill; 2001:399-428.
4. Physicians' desk reference. Package insert for propranol. Montvale, NJ: Thomson PDR; 2003.
5. Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: Phenomenology, course, risk factors and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990;10:88-95.
6. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clinical Pharmacokinetics 1995;29:192-209.
7. Glassman AH, Johnson LL, Giardina EG, et al. The use of imipramine in depressed patients with congestive heart failure. JAMA 1983;250:1997-2001.
8. Keller MB, Klerman GL, Lavori PW, et al. Treatment received by depressed patients. JAMA 1982;248:1848-55.
9. Appleton WS. Fourth psychoactive usage guidelines. J Clin Psychiatry 1982;42:12-27.
10. McLellan RA, Oscarson M, Seidegard J, et al. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997;7:187-91.
11. Teh LK, Ismail R, Yusoff R, et al. Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J Clin Pharm Ther 2001;26:205-11.
12. Agundez JA, Gallardo L, Ledesma MC, et al. Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. Oncology 2001;61:59-63.
13. Ingelman-Sundberg M. Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development. Drug Metab Dispos 2001;29(4 Pt 2):570-3.
14. Preskorn SH. Modern drug development and the human genome project (collection of columns published in the Journal of Psychiatric Practice). Available at http://www.preskorn.com/column4.html.
15. Burrows GD, Norman TR. Tricyclic antidepressants: Plasma levels and clinical response. In: Burrows GD, Norman TR, eds. Psychotropic drugs; Plasma concentration and clinical response. New York: Marcel Dekker; 1981:69-204.
16. Asberg M. Individualization of treatment with tricyclic compounds. Med Clin North Am 1974;58:1083-91.
17. Alexanderson B, Sjoqvist F. Individual differences in the pharmacokinetics of monomethylated tricyclic antidepressants: Role of genetic and environmental factors and clinical importance. Ann NY Acad Sci 1971;179:739-51.
18. Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988;331:442-6.
19. Gonzalez FJ, Vilbois F, Hardwick JP, et al. Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 1988;2:174-9.
20. Kimura S, Umeno M, Skoda RC, et al. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989;45:889-904
21. Preskorn SH. A message from Titanic. J Pract Psychiatry Behav Health 1998;4:236-42.
22. Preskorn SH. The slippery slide. J Pract Psychiatry Behav Health 1999;5:50-5.
23. Preskorn SH. Do you believe in magic?. J Pract Psychiatry Behav Health 1997;3:99-103.
24. Preskorn SH. What happened to Tommy? J Pract Psychiatry Behav Health 1998;4:363-7/
25. Preskorn SH. Clinical pharmacology case conference: A suicide attempt? Journal of Psychiatric Practice 2002;8:306-10.
26. Preskorn SH. Antipsychotic drug development in the prehuman-genome era: A full circle. Journal of Practical Psychiatry 2001;7:209-13.
27. Preskorn SH. The rationale for and clinical implications of dose-response curvese project (collection of columns published in J Pract Psychiatry Behav Health). Available at http://www.preskorn.com2column3.html.
28. Preskorn SH. Therapeutic drug monitoring. In: Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo, OK: Professional Communications; 1996: 99-105. Available at http://www.preskorn.com/books.html.
29. Preskorn SH. The stages of drug development and the human genome project: Drug discovery. Journal of Psychiatric Practice 2000;6:341-4.
30. Preskorn SH. Bridging the gap. Available at http://www.preskorn.com2columns/0012.html
31. Preskorn SH. A tale of two patients. J Pract Psychiatry Behav Health 1999;5:160-4.
32. Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants: Cost implications and relevance to clinical practice. Clinical Pharmacokinetics 1999;37:147-65.